STOCK TITAN

AN2 Therapeutics, Inc. (ANTX) EPS by Year

ANTX

AN2 Therapeutics, Inc. lost $1.16 per diluted share in fiscal year 2025. This represents an increase of 32.6% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to a loss of $1.06 per diluted share. The table below carries 5 fiscal years, from 2021 to 2025, and the quarters AN2 Therapeutics, Inc. has filed alongside them.

FY2025 annual
EPS (Diluted) -$1.16
YoY +32.6%
Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

ANTX EPS (Diluted) by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricTTMFY2510-KFY2410-KFY2310-KFY2210-KFY2110-K
EPS (Diluted)-$1.06-$1.16+32.6%-$1.72+37.2%-$2.74-$2.79-$10.64

TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.

ANTX EPS (Diluted) by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-KQ3'2310-Q
EPS (Diluted)-$0.18+14.3%-$0.29+17.1%-$0.28-12.0%-$0.31+27.9%-$0.21+56.3%-$0.35+37.5%-$0.25+51.9%-$0.43+33.8%-$0.48-$0.56-$0.52+10.3%-$0.65-10.2%

What diluted earnings per share means

Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.

More AN2 Therapeutics, Inc. financials

Frequently Asked Questions

What was AN2 Therapeutics, Inc.'s diluted earnings per share in fiscal year 2025?

AN2 Therapeutics, Inc. lost $1.16 per diluted share in fiscal year 2025.

How fast is AN2 Therapeutics, Inc.'s diluted earnings per share growing?

AN2 Therapeutics, Inc. (ANTX) diluted earnings per share rose by 32.6% year over year, from -$1.72 to -$1.16 in fiscal year 2025.

What is AN2 Therapeutics, Inc.'s diluted earnings per share over the last twelve months?

AN2 Therapeutics, Inc. (ANTX) reported a loss of $1.06 per diluted share over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.

Across the 5 fiscal years this page covers, AN2 Therapeutics, Inc. (ANTX) diluted earnings per share went from -$10.64 in fiscal year 2021 to -$1.16 in fiscal year 2025.

AN2 Therapeutics, Inc. (ANTX) reported -$0.18 in diluted earnings per share in Q2 2026. This represents an increase of 14.3% from the same quarter a year earlier.

Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what AN2 Therapeutics, Inc. (ANTX) reported on that line in every period on record.